Low-dose naltrexone (LDN) hope for patients with longCOVID syndrome?
07 August 2022
Scientists from the Medical University of Dublin have conducted a study on the effects of low-dose naltrexone - the so-called LDN (Low Dose Naltrexone) therapy for the relief of symptoms in patients with long-COVID, which was described in the article: “Safety and efficacy of low dose naltrexone in a long covid cohort; an interventional pre-post study” recently published online on the Brain Behavior & Immunity Health website.
Low-dose naltrexone was mentioned among the substances that may improve immunity during the COVID-19 pandemic. Off-label LDN practitioners for a variety of medical conditions have reported fewer cases of COVID-19 among LDN users, and COVID-19 users with low-dose naltrexone tended to be mild in their disease. Already at the beginning of the pandemic, a study of the effectiveness of LDN in the treatment of COVID-19 was started. Research is currently underway, including Phase II pilot studies assessing, among others, the effectiveness of low doses of naltrexone (LDN) in the case of symptoms of long COVID.
According to the authors of the study, LDN therapy is safe in patients with longCOVID syndrome and may reduce the symptomatology in this group of patients. However, due to the numerous limitations of this study, including a small group of subjects or the lack of a control group, it is necessary to conduct a randomized control study to reliably assess the effectiveness of LDN therapy in patients with longCOVID.